{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:48:20Z","timestamp":1794361700451,"version":"4.9.0"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,6,2]],"date-time":"2006-06-02T00:00:00Z","timestamp":1149206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Late\u2010stage prostate cancer patients are refractory to hormone therapy and exhibit a high propensity to develop skeletal metastasis. In this regard, the role of a novel cytokine system belonging to the tumor necrosis factor (TNF) family that is critical for osteoclastic osteolysis and that consists of receptor activator of NF\u2010\u03baB ligand (RANKL), its receptor (RANK), and decoy receptor osteoprotegerin (OPG) is of potential interest.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Reverse\u2010transcriptase polymerase chain reaction (RT\u2010PCR) and immunohistochemical analysis was used to examine the expression of RANKL, RANK, and OPG in human prostate cancer cell lines and in 89 archival samples of primary and metastatic (lymph nodes, skeleton) prostate cancer patients. Expression of these proteins was correlated with clinicopathogic parameters of the prostate cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Expression of RANKL\/RANK\/OPG was low in normal but markedly higher in prostate cancer cell lines. Analysis of surgical biopsy specimens showed the expression of RANKL (31%), RANK (38%), and OPG (19%) in primary carcinoma. The expression frequency was significantly higher (RANKL [44%], RANK [49%], and OPG [73%]) in metastatic prostate cancer. OPG (83%) production was more common in skeletal as compared with lymph node metastases (46%), whereas the expression of RANKL expression was less discordant in bone (47%) and lymph node metastases (36%). The increased expression of RANKL\/RANK\/OPG observed correlated with Gleason score, TNM stage, androgen status, and serum prostate\u2010specific antigen (PSA) levels in the prostate cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Expression of RANKL\/RANK\/OPG correlates with more aggressive, advanced, metastatic prostate carcinoma to suggest their role as diagnostic, prognostic, and therapeutic targets for prostate cancer. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21978","type":"journal-article","created":{"date-parts":[[2006,6,2]],"date-time":"2006-06-02T17:29:51Z","timestamp":1149269391000},"page":"289-298","source":"Crossref","is-referenced-by-count":183,"title":["Expression of RANKL\/RANK\/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation"],"prefix":"10.1002","volume":"107","author":[{"given":"Gaoping","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanishka","family":"Sircar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Aprikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Potti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goltzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafaat A.","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.1.10"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/46303"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1998.9788"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.12.9.1260"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.18.2412"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1998.8697"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc867"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.162.11.1"},{"key":"e_1_2_5_13_2","first-page":"5438","article-title":"Receptor activator of nuclear factor\u2010kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia AN","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64942-5"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/mp.56.2.116"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20308"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21008"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2784"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63560-2"},{"key":"e_1_2_5_20_2","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony S","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1583"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/74999"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11134"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11138"},{"key":"e_1_2_5_25_2","first-page":"1619","article-title":"Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells","volume":"62","author":"Holen I","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11685"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-004-2869-0"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20314"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2005.026955"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20518"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2002.00514.x"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01122-5"},{"issue":"1","key":"e_1_2_5_33_2","first-page":"S1117","article-title":"Receptor activator of NK\u2010kappaB ligand influences malignant activities of metastatic breast cancer cells","volume":"20","author":"Ray MR","year":"2005","journal-title":"J Bone Miner Res."},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.04.013"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-2419-8"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-003-0845-8"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20550"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10662"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2033"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00434-9"},{"key":"e_1_2_5_41_2","first-page":"S63","article-title":"Fc\u2010OPG inhibits osteoclast activity while tumor\u2010derived OPG enhances tumor growth","volume":"18","author":"Fisher JL","year":"2003","journal-title":"J Bone Miner Res."}],"updated-by":[{"DOI":"10.1002\/cncr.31640","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000}}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21978","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:23:57Z","timestamp":1760271837000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,7,15]]}},"alternative-id":["10.1002\/cncr.21978"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21978","archive":["Portico"],"relation":{"erratum":[{"id-type":"doi","id":"10.1002\/cncr.31640","asserted-by":"object"}]},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,5]]}}}